Dataset Information


EGFRvIII/integrin ?3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.

ABSTRACT: Glioblastoma (GBM) is one of the most lethal brain tumors with a short survival time. EGFR amplification and mutation is the most significant genetic signature in GBM. About half of the GBMs with EGFR amplification express a constitutively autophosphorylated variant of EGFR, known as EGFRvIII. Our in vitro data demonstrated further enhanced EGFRvIII activity and tumor cell invasion in the tumor microenvironment of hypoxia plus extracellular matrix (ECM) vitronectin, in which EGFRvIII and integrin ?3 tended to form complexes. The treatment with ITGB3 siRNA or the integrin antagonist cilengetide preferentially interrupted the EGFRvIII/integrin ?3 complex, effectively reduced tumor cell invasion and activation of downstream signaling effectors. Cilengitide is recently failed in Phase III CENTRIC trial in unselected patients with GBM. However, we found that cilengitide demonstrated efficacious tumor regression via inhibition of tumor growth and angiogenesis in EGFRvIII orthotopic xenografts. Bioinformatics analysis emphasized key roles of integrin ?3, hypoxia and vitronectin and their strong correlations with EGFRvIII expression in malignant glioma patient samples in vivo. In conclusion, we demonstrate that EGFRvIII/integrin ?3 complexes promote GBM progression and metastasis in the environment of hypoxia and vitronectin-enrichment, and cilengitide may serve as a promising therapeutics for EGFRvIII-positive GBMs.


PROVIDER: S-EPMC4826235 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5737576 | BioStudies
1000-01-01 | S-EPMC5762005 | BioStudies
2009-01-01 | S-EPMC2759716 | BioStudies
1000-01-01 | S-EPMC4029392 | BioStudies
2015-01-01 | S-EPMC4539240 | BioStudies
1000-01-01 | S-EPMC5791772 | BioStudies
1000-01-01 | S-EPMC5999169 | BioStudies
2017-01-01 | S-EPMC5482605 | BioStudies
2013-01-01 | S-EPMC6493376 | BioStudies
2016-01-01 | S-EPMC4891076 | BioStudies